Reuters logo
in 3 months
BRIEF-Bluebird Bio enters into patent license agreement with Glaxosmithkline for commercialization of Gene Therapies
May 2, 2017 / 12:11 PM / in 3 months

BRIEF-Bluebird Bio enters into patent license agreement with Glaxosmithkline for commercialization of Gene Therapies

May 2 (Reuters) - Bluebird Bio Inc

* Bluebird bio enters lentiviral vector patent license agreement with Glaxosmithkline for commercialization of gene therapies

* Bluebird bio - under terms of agreement, gsk will non-exclusively license certain bluebird patent rights related to lentiviral vector technology

* Bluebird bio- financial terms of agreement include an upfront payment to bluebird as well as potential development and regulatory milestone payments

* Bluebird bio inc - financial terms of agreement also include low single digit royalties on net sales of covered products Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below